<DOC>
	<DOCNO>NCT00684268</DOCNO>
	<brief_summary>By chance investigator find iv . silibinin potent antiviral effect hepatitis C virus . Based result dose find study ( publish ) te optimum dose schedule explored.This study evaluate whether high active dose give optimal time combine standard care result sustain virologic response ( =cure hepatitis C ) .</brief_summary>
	<brief_title>Intravenous Silibinin Combination With Peg-interferon Ribavirin Nonresponders</brief_title>
	<detailed_description>Since publication first data optimal dosing schedule investigate</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Silybin</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<criteria>Nonresponders full dose PEGIFN/RBV therapy Liver biopsy within last 2 year Intolerance one study drug Coinfection HIV/HBV</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>silibinin</keyword>
	<keyword>chronic hepatitis C</keyword>
	<keyword>peginterferon</keyword>
	<keyword>ribavirin</keyword>
	<keyword>nonresponders</keyword>
	<keyword>efficacy iv . silibinin</keyword>
	<keyword>safety</keyword>
</DOC>